StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Agomab Therapeutics (AGMB)

Wed, 21 Oct 2026 06:51:44 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $35.00 price target on Agomab Therapeutics (NASDAQ: AGMB).

The analyst commented: "Fibroinflammation panel highlights the need to move beyond inflammatory control; reiterate Buy. At the October 18 Johnson & Johnson (JNJ; not rated)–organized United European Gastroenterology (UEG) Week panel, “The fibroinflammation frontier: rewiring the stroma in inflammatory GI disease,” AgomAb's CEO Tim Knotnerus discussed the potential importance of addressing both inflammation and fibrosis to modify disease progression in inflammatory bowel disease (IBD). Panelists highlighted a persistent treatment gap: stricturing disease and symptoms associated with structural damage can remain despite successful anti-inflammatory

Form 6-K AgomAb Therapeutics NV For: Oct 13

Tue, 13 Oct 2026 17:18:00 -0400

si-local-file:///var/storage/secattach/20261013/27181971.html

Agomab doses first patient in Phase 2b Crohn's disease study

Tue, 13 Oct 2026 16:05:17 -0400

Agomab Therapeutics NV announced that the first patient has been dosed in NOV-ERA, a global Phase 2b study evaluating ontunisertib in patients with symptomatic fibrostenosing Crohn's disease (FSCD), according to a company statement dated October 13, 2026.

NOV-ERA is a randomized, double-blind, placebo-controlled, multicenter trial expected to enroll approximately 320 adult patients globally. Participants will be randomized to receive ontunisertib at one of three dose levels — 400 mg, 200 mg, or 100 mg administered twice daily — or a matching placebo over a 52-week treatment period. The primary endpoint is the proportion of patients achieving endoscopic passability of the ileal

Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease

Tue, 13 Oct 2026 16:05:00 -0400

-- NOV-ERA is designed to assess the efficacy and safety of ontunisertib in approximately 320 patients with symptomatic Fibrostenosing Crohn's disease (FSCD) --

-- Global, randomized, placebo-controlled, dose-ranging study to evaluate three dose levels of ontunisertib, with endoscopic passability at Week 24 as primary endpoint --

-- Study initiation represents an important milestone in the development of ontunisertib as a potential first targeted anti-fibrotic treatment for FSCD --

Antwerp, Belgium, October 13, 2026 – Agomab Therapeutics NV (‘Agomab’), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that the

Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease

Tue, 13 Oct 2026 16:05:00 -0400

-- NOV-ERA is designed to assess the efficacy and safety of ontunisertib in approximately 320 patients with symptomatic Fibrostenosing Crohn's disease (FSCD) --

-- Global, randomized, placebo-controlled, dose-ranging study to evaluate three dose levels of ontunisertib, with endoscopic passability at Week 24 as primary endpoint --

-- Study initiation represents an important milestone in the development of ontunisertib as a potential first targeted anti-fibrotic treatment for FSCD --

Antwerp, Belgium, October 13, 2026 – Agomab Therapeutics NV (‘Agomab’), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that the

Form 4 AgomAb Therapeutics NV For: Oct 08 Filed by: Epstein David R

Fri, 09 Oct 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20261009/27169374.html

Form 4 AgomAb Therapeutics NV For: Oct 05 Filed by: Epstein David R

Wed, 07 Oct 2026 08:57:00 -0400

si-local-file:///var/storage/secattach/20261007/27158700.html

Form 4 AgomAb Therapeutics NV For: Oct 06 Filed by: Kemula Pierre Thadee Victor

Wed, 07 Oct 2026 08:47:00 -0400

si-local-file:///var/storage/secattach/20261007/27158647.html

Form 4 AgomAb Therapeutics NV For: Oct 05 Filed by: Knotnerus Tim Jasper

Wed, 07 Oct 2026 08:07:00 -0400

si-local-file:///var/storage/secattach/20261007/27158332.html

H.C. Wainwright Reiterates Buy Rating on Agomab Therapeutics (AGMB)

Fri, 02 Oct 2026 06:59:31 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $35.00 price target on Agomab Therapeutics (NASDAQ: AGMB).

The analyst commented: "This morning, Agomab announced topline results from the 48-week open-label extension (OLE) of the Phase 2a STENOVA trial evaluating ontunisertib, an oral, gut-restricted ALK5 inhibitor, in fibrostenosing Crohn’s disease (FSCD). The key findings were a generally favorable safety and tolerability profile through up to 60 weeks of total treatment and only one FSCD-related intervention—an endoscopic balloon dilation—with no surgeries and a reported annualized event rate of 3%. We view the STENOVA data as supportive of extended dosing, while management reiterated

Agomab stock jumps on positive trial data

Thu, 01 Oct 2026 09:05:58 -0400

Investing.com -- Agomab Therapeutics Nv (NASDAQ:AGMB) shares rose 6.3% in premarket trading Thursday following positive topline results from the open-label extension study of its experimental drug ontunisertib for fibrostenosing Crohn's disease.

The company reported favorable safety and tolerability data through up to 60 weeks of treatment in the STENOVA trial extension study. The trial showed a low annualized disease-related event rate of 3%, with one endoscopic balloon dilation and no surgeries reported during the full treatment period.

Of the 49 patients who entered the 48-week open-label extension, representing 94% of eligible participants from the initial 12-week placebo-controlled portion, 37

Agomab stock jumps on positive trial data

Thu, 01 Oct 2026 09:05:58 -0400

Of the 49 patients who entered the 48-week open-label extension, representing 94% of eligible participants from the initial 12-week placebo-controlled portion, 37

Form 6-K AgomAb Therapeutics NV For: Oct 01

Thu, 01 Oct 2026 06:42:00 -0400

si-local-file:///var/storage/secattach/20261001/27131149.html

Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease

Thu, 01 Oct 2026 06:30:00 -0400

-- Favorable safety and tolerability profile maintained through up to 60 weeks of treatment with ontunisertib in Fibrostenosing Crohn’s disease (FSCD) patients --

-- Low annualized FSCD-related event rate of 3%, with one endoscopic balloon dilation (EBD) and no surgeries reported over the full treatment period --

-- Radiological assessment shows trend for fibrotic stricture stabilization over treatment course --

-- Sustained disease control observed across symptoms and disease activity scores in Open-Label Extension Study (OLE) --

-- Results support initiation of global NOV-ERA Phase 2b study in FSCD in the coming

Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease

Thu, 01 Oct 2026 06:30:00 -0400

-- Favorable safety and tolerability profile maintained through up to 60 weeks of treatment with ontunisertib in Fibrostenosing Crohn’s disease (FSCD) patients --

-- Low annualized FSCD-related event rate of 3%, with one endoscopic balloon dilation (EBD) and no surgeries reported over the full treatment period --

-- Radiological assessment shows trend for fibrotic stricture stabilization over treatment course --

-- Sustained disease control observed across symptoms and disease activity scores in Open-Label Extension Study (OLE) --

-- Results support initiation of global NOV-ERA Phase 2b study in FSCD in the coming

H.C. Wainwright Reiterates Buy Rating on Agomab Therapeutics (AGMB)

Wed, 16 Sep 2026 06:58:09 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $35.00 price target on Agomab Therapeutics (NASDAQ: AGMB).
The analyst commented: "AGMB-447 proof of mechanism in IPF patients supports advancement to Phase 2 INSPIRIA trial this year. On September 14, after the market closed, Agomab reported positive topline results from Part C of the AGMB-447 Phase 1 study — 10 idiopathic pulmonary fibrosis (IPF) patients dosed over 14 days — and disclosed the design of INSPIRIA, its planned Phase 2 trial. The topline data cleared the bar we set in our June 22 initiation report: 1) a generally favorable safety and

Form 4 AgomAb Therapeutics NV For: Sep 11 Filed by: Garcia Marino

Tue, 15 Sep 2026 16:07:00 -0400
si-local-file:///var/storage/secattach/20260915/27064892.html

Form 3 AgomAb Therapeutics NV For: Sep 11 Filed by: Patel Naimish

Tue, 15 Sep 2026 16:06:00 -0400
si-local-file:///var/storage/secattach/20260915/27064874.html

Form 3 AgomAb Therapeutics NV For: Sep 11 Filed by: Garcia Marino

Tue, 15 Sep 2026 16:06:00 -0400
si-local-file:///var/storage/secattach/20260915/27064879.html

Form 4 AgomAb Therapeutics NV For: Sep 11 Filed by: Patel Naimish

Tue, 15 Sep 2026 16:06:00 -0400
si-local-file:///var/storage/secattach/20260915/27064885.html

Form 6-K Agomab Therapeutics NV For: Sep 14

Mon, 14 Sep 2026 16:15:00 -0400
si-local-file:///var/storage/secattach/20260914/27058593.html

Form 6-K Agomab Therapeutics NV For: Sep 11

Fri, 11 Sep 2026 17:03:00 -0400
si-local-file:///var/storage/secattach/20260911/27053583.html

Agomab adds two members to its board of directors

Fri, 11 Sep 2026 16:05:28 -0400

Agomab Therapeutics NV (Nasdaq: AGMB) announced that shareholders approved the appointments of Marino Garcia and Naimish Patel, M.D., as non-executive members of the company's board of directors at a Special and Extraordinary General Shareholders' Meeting held on September 11, 2026, in Antwerp, Belgium.

Shareholders also approved a consolidation and split adjustment of outstanding pre-initial public offering warrants, aligning them with a share split implemented in connection with Agomab's IPO in February 2026.

Tim Knotnerus, Chief Executive Officer of Agomab, said, "Both bring exceptional and complementary experience that will be highly valuable as we continue to advance our portfolio of potential disease-modifying therapies

Agomab adds two members to its board of directors

Fri, 11 Sep 2026 16:05:09 -0400

Agomab Therapeutics NV (Nasdaq: AGMB) announced that shareholders approved the appointments of Marino Garcia and Naimish Patel, M.D., as non-executive members of its board of directors at a Special and Extraordinary General Shareholders' Meeting held on September 11, 2026.

The clinical-stage biopharmaceutical company, focused on fibro-inflammatory diseases, said shareholders also approved the consolidation and split adjustment of outstanding pre-initial public offering warrants, aligning them with the share split implemented in connection with Agomab's IPO in February 2026.

Tim Knotnerus, Chief Executive Officer of Agomab, said both appointees "bring exceptional and complementary experience that will be highly valuable as we continue to advance

Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors

Fri, 11 Sep 2026 16:05:00 -0400

Antwerp, Belgium, September 11, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the “Company”), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that shareholders approved all resolutions submitted for consideration at the Company's Special and Extraordinary General Shareholders' Meeting held on September 11, 2026. The approved resolutions included the appointments of Marino Garcia and Naimish Patel, M.D. as non-executive members of the Company's Board of Directors and the proposed consolidation and split adjustment of outstanding pre-Initial Public Offering (IPO) warrants.

“We are grateful for the support of our shareholders and excited to formally welcome